Quality and Regulatory Sourcebook eBook
Read the article:
In-Use Testing of Cleanroom Garments
Read the eBook:
BioPharm International’s Quality and Regulatory Sourcebook eBook
In-Use Testing of Cleanroom Garments
Publication
Article
BioPharm InternationalBioPharm International, Regulatory Sourcebook March 2022
Volume 2022 eBook
Issue 1
Pages: 10–11, 29
Testing cleanroom garments while in use and during daily cleanroom operations is vital for contamination control.
Warut/Stock.adobe.com
Contamination is a serious issue in cleanroom operations, and controlling contamination generated by human operators and their clothing is a major concern. People disperse large numbers of particles that vary in number from person to person and over time. Thus, cleanroom garments must be designed to protect the environment and the process by containing the particles generated by the person while not becoming a source of contamination. An important decision that faces the manager of any cleanroom is the selection of a cleanroom garment or garment system, according to Anne Marie Dixon-Heathman, principal, Cleanroom Management Associates. Following up on a presentation given by Dixon-Heathman at INTERPHEX 2021 on in-use testing of garments, BioPharm International spoke to Dixon-Heathman for further insight.
Read this article in BioPharm International’s March 2022 Quality and Regulatory Sourcebook eBook.
About the author
Feliza Mirasol is the science editor for BioPharm International.
Article Details
BioPharm International
eBook: Quality and Regulatory Sourcebook, March 2022
March 2022
Pages: 10–11, 29
Citation
When referring to this article, please cite it as F. Mirasol, “In-Use Testing of Cleanroom Garments," BioPharm International Quality and Regulatory Sourcebook eBook (March 2022).
Articles in this issue
In-Use Testing of Cleanroom Garments
How a Lack of Critical Thinking is Hindering Regulatory Compliance
Contextualizing Computer Validation
Assessing the Quality of CAR-T Cells Using ddPCR
The Data Relationship
Supply Chain Considerations for Ensuring Quality
DSCSA’s Next Big Hurdle
A New Route to Pharma GDP Compliance and Standardization
Remote Inspections - Lessons Learned
Recent Videos
Related Content
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025Article
The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Article
Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
